โน๏ธ What is Follicular Lymphoma (FL)?
๐ Primary Treatment Approaches
Follicular Lymphoma treatment ranges from active surveillance (watch-and-wait) for asymptomatic patients to chemoimmunotherapy, targeted agents, and CAR T when needed:
๐ฌ Disease Biology
Follicular Lymphoma arises from germinal center B-cells and is characterized by a waxing and waning clinical course โ lymph nodes may enlarge, then spontaneously shrink, then re-enlarge months later. This natural history makes watchful waiting a legitimate strategy and complicates the assessment of whether treatment is truly working.
t(14;18) โ The BCL2 Translocation
The hallmark of FL is the t(14;18)(q32;q21) translocation, placing the BCL2 gene under control of the immunoglobulin heavy chain promoter. BCL2 is an anti-apoptotic protein โ its overexpression allows follicular B-cells to resist programmed cell death and accumulate indefinitely. This translocation is detectable in ~85โ90% of FL cases.
FL Grading (1โ3)
FL is graded 1โ3 based on the number of large centroblasts per high-power field. Grade 1 and 2 are considered indolent; Grade 3A is intermediate. Grade 3B FL is treated like DLBCL โ with R-CHOP-based therapy โ as it behaves aggressively and may not carry the BCL2 translocation.
๐ FLIPI โ Follicular Lymphoma International Prognostic Index
The FLIPI predicts prognosis in FL. Each of the following adverse factors scores 1 point:
๐ Treatment Approaches
Asymptomatic, low-burden disease (Stage IโII or low FLIPI)
Randomized trials show that immediate treatment does NOT improve overall survival in asymptomatic FL patients. Active surveillance with regular monitoring (exam, CBC, CT/PET-CT) is the standard of care. Treatment is deferred until GELF criteria are met (symptomatic, bulky disease, organ compromise, rapidly progressive, or cytopenias).
Preferred first-line induction for most symptomatic FL
The BRIGHT and StiL trials showed BR is superior to R-CHOP/R-CVP in PFS for indolent lymphoma with less toxicity (less alopecia, neuropathy). BR is the preferred induction for most FL patients who require treatment.
Alternative induction; preferred if rituximab-refractory
Obinutuzumab is a glycoengineered anti-CD20 antibody with superior ADCC vs rituximab. GALLIUM trial: Obinutuzumab-chemo significantly improved PFS vs rituximab-chemo, at the cost of more toxicity. Obinutuzumab maintenance for 2 years after induction is approved.
Relapsed/refractory FL with EZH2 mutation (or any regardless)
Tazemetostat is a first-in-class EZH2 histone methyltransferase inhibitor. FDA-approved for adults with relapsed/refractory FL whose tumors are EZH2-mutated (higher response rate) or who have no satisfactory alternative options regardless of mutation status. An oral, once-daily tablet.
3rd line+ relapsed/refractory FL
Axicabtagene ciloleucel (axi-cel, Yescarta) is FDA-approved for relapsed/refractory FL after at least 2 prior lines of therapy. The ZUMA-5 trial showed an 86% ORR (69% CR) in heavily pre-treated indolent NHL. A potentially curative option for some FL patients.
โ ๏ธ Histologic Transformation to DLBCL
Approximately 2โ3% per year of FL patients experience histologic transformation to Diffuse Large B-Cell Lymphoma (DLBCL) โ a significantly more aggressive disease requiring immediate, intensified treatment.
Warning Signs of Transformation:
- โข Rapidly enlarging lymph node(s) โ sudden growth after a period of stability
- โข B symptoms (fever, night sweats, weight loss) appearing for the first time
- โข New extranodal disease or bone marrow involvement
- โข Discordantly high LDH relative to tumor burden
- โข New sites of FDG-PET avidity (especially a single very "hot" node)
Any of these warrant urgent biopsy of the most active site. Transformed FL is treated with DLBCL regimens, and CAR T-cell therapy is an option for eligible patients.
๐ ๏ธ Tools & Focused Research
Scientific Literature
Search thousands of PubMed articles curated for Follicular Lymphoma.
Clinical Trials
Explore actively recruiting clinical trials for this disease group.
View Clinical Trials